Question 2: Antiviral treatment of varicella in adult or immunocompromisedpatients

Authors
Citation
S. Alfandari, Question 2: Antiviral treatment of varicella in adult or immunocompromisedpatients, MED MAL INF, 28(11), 1998, pp. 722-729
Citations number
30
Categorie Soggetti
Clinical Immunolgy & Infectious Disease
Journal title
MEDECINE ET MALADIES INFECTIEUSES
ISSN journal
0399077X → ACNP
Volume
28
Issue
11
Year of publication
1998
Pages
722 - 729
Database
ISI
SICI code
0399-077X(199811)28:11<722:Q2ATOV>2.0.ZU;2-1
Abstract
A search of the English and French Literature from 1980 or 1997 identified 20 papers (excluding isolated cases reports) on the treatment of adult vari cella. Most of these studies are ancient with an insufficient methodology. Only 7 are randomized and only 6, open labeled or retrospective, include mo re than 10 patients. Three studies compare acyclovir versus placebo in 316 immunocompetent adults with uncomplicated varicella, Only one has a correct methodology. Acyclovir showed a benefit on all studied parameters only for patients treated in the 24 h following eruption. One study randomised sori vudine versus placebo in 186 patients. A reduction of duration of fever and hospitalization was noted in patients receiving sovirudine. However, frequ ency or duration of symptoms was only decreased in patients treated in the 24 h following eruption. Two studies evaluating open label acyclovir displa yed a benefit only for early therapy. For the treatment of complicated vari cella in immunocompetent patients, only open label studies are available. A mong 56 patients receiving early acyclovir, only 2 deaths are observed. Pap ers on immunodepressed patients often associated varicella and tester. The two randomized studies include only 14 varicella among 66 patients. The lar gest retrospective study includes 57 varicella among 113 patients, Treatmen ts used include acyclovir, sorivudine, adenine arabinoside or varicella tes ter immune globulins. Only 12 deaths are observed among 113 treated varicel la. Analyses of experts recommendations shows a consensus for treating comp licated varicella and conflicting opinions for the treatment of uncomplicat ed varicella in the immunocompetent adult. The treatment of uncomplicated v aricella in the immunocompetent adult shows a modest benefit. Treatment of complicated varicella or of the immunocompromised host is highly beneficial , however, comparative studies of a sufficient power are needed to evaluate the efficacy of treatment on varicella mortality.